Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share IRVING, Texas --(BUSINESS WIRE)--Feb. 20, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized

IRVING, Texas --(BUSINESS WIRE)--Jan. 25, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved

Strategic and accretive transaction enables vertical integration of hormone product manufacturing IRVING, Texas --(BUSINESS WIRE)--Jan. 17, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized

IRVING, Texas --(BUSINESS WIRE)--Jan. 17, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and

IRVING, Texas --(BUSINESS WIRE)--Jan. 11, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named

Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance IRVING, Texas --(BUSINESS WIRE)--Nov. 7, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced

IRVING, Texas --(BUSINESS WIRE)--Oct. 24, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide third quarter financial results on Tuesday, November 7, 2023 , after the close of the market.

Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men’s Health Categories IRVING, Texas --(BUSINESS WIRE)--Aug. 10, 2023-- Biote (NASDAQ: BTMD), a leading solutions

IRVING, Texas --(BUSINESS WIRE)--Jul. 27, 2023-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of hormone optimization, today announced the Company will provide second quarter financial results on Thursday, August 10, 2023 , after the close of the market.

Leader in Hormone Education and Training Aims to Increase Awareness and Access to Testosterone Deficiency Therapy through Expanded Network of Urologists and Internal Medicine Practitioners IRVING, Texas --(BUSINESS WIRE)--Jun. 22, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a